Bioniz Therapeutics
Bioniz Therapeutics is a clinical-stage biopharmaceutical company focused on transforming drug development for immune-driven diseases through the targeted and selective modulation of cytokines. Utilizing their proprietary Multi Modal Modulation (M3) technology platform, they develop next-generation anti-cytokine therapeutics that can inhibit multiple cytokines simultaneously while maintaining normal immune function. Their mission is to address complex autoimmune and cancer-related diseases by creating innovative peptide therapeutics that selectively inhibit cytokine pathways, overcoming the limitations of current therapies.
Industries
Nr. of Employees
small (1-50)
Patents
Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
US-12030936-B2
View Details
Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
US-12030936-B2
View DetailsProducts
BNZ-1 (PEGylated multi-cytokine inhibitory peptide)
PEGylated peptide therapeutic designed to selectively inhibit interleukins IL-2, IL-9, and IL-15; developed and studied in Phase 1/2 clinical trials for T-cell malignancies and investigated for autoimmune dermatological indications.
BNZ-2 (multi-cytokine inhibitory peptide targeting IL-15/IL-21)
Peptide therapeutic designed to selectively inhibit IL-15 and IL-21, intended for inflammatory diseases of the gastrointestinal tract and other IL-15/IL-21 driven conditions.
BNZ-3 (orally bioavailable multi-cytokine inhibitory peptide)
Peptide candidate designed for oral administration with stability in gastric and intestinal fluids; intended to inhibit selected cytokines (IL-15/IL-21) for GI and systemic indications.
M3 Technology Platform (Multi Modal Modulation)
Discovery and design platform combining cytokine biology knowledge and computational methods to create peptide therapeutics that selectively inhibit combinations of cytokines.
BNZ-1 (PEGylated multi-cytokine inhibitory peptide)
PEGylated peptide therapeutic designed to selectively inhibit interleukins IL-2, IL-9, and IL-15; developed and studied in Phase 1/2 clinical trials for T-cell malignancies and investigated for autoimmune dermatological indications.
BNZ-2 (multi-cytokine inhibitory peptide targeting IL-15/IL-21)
Peptide therapeutic designed to selectively inhibit IL-15 and IL-21, intended for inflammatory diseases of the gastrointestinal tract and other IL-15/IL-21 driven conditions.
BNZ-3 (orally bioavailable multi-cytokine inhibitory peptide)
Peptide candidate designed for oral administration with stability in gastric and intestinal fluids; intended to inhibit selected cytokines (IL-15/IL-21) for GI and systemic indications.
M3 Technology Platform (Multi Modal Modulation)
Discovery and design platform combining cytokine biology knowledge and computational methods to create peptide therapeutics that selectively inhibit combinations of cytokines.
Expertise Areas
- Peptide therapeutics discovery
- Cytokine biology and immunology
- Clinical trial management and design
- Translational medicine and clinical pharmacology
Key Technologies
- Peptide-based multi-cytokine inhibitors
- PEGylation
- In silico machine learning for drug design
- Receptor-interface structure-guided design
News & Updates
Bioniz announces positive efficacy and safety data for BNZ-1 from interim analysis of phase 1/2 study in cutaneous T-cell lymphoma
Interim clinical data from a Phase 1/2 study of BNZ-1 in patients with refractory Cutaneous T-Cell Lymphoma shows meaningful clinical impact, with over 80% showing some tumor burden improvement, and about half achieving partial response.
Bioniz announces positive end of Phase 2 meeting with the FDA for BNZ-1 for the treatment of refractory cutaneous T-cell lymphoma
The FDA provided positive feedback and guidance for a Phase 3 trial of BNZ-1 in rCTCL, with plans to start enrollment in the second half of 2021.
Bioniz Therapeutics reports top-line Phase 1 clinical study results for BNZ-1, a novel multi-cytokine inhibitor
Favorable safety, pharmacokinetics, and pharmacodynamic activity demonstrated in healthy volunteers, supporting further clinical development.
Bioniz Therapeutics initiates Phase 1/2 clinical study of BNZ-1 in T-cell leukemia and lymphoma
A multi-center, open-label, dose-escalation study to assess safety and activity of BNZ-1 in patients with T-cell malignancies.
Bioniz Therapeutics announces positive clinical data of BNZ-1 in refractory CTCL
BNZ-1 showed an overall response rate of 63.2%, with a complete response in one patient and partial responses in eleven, demonstrating efficacy in heavily pretreated patients.
Bioniz announces positive efficacy and safety data for BNZ-1 from interim analysis of phase 1/2 study in cutaneous T-cell lymphoma
Interim clinical data from a Phase 1/2 study of BNZ-1 in patients with refractory Cutaneous T-Cell Lymphoma shows meaningful clinical impact, with over 80% showing some tumor burden improvement, and about half achieving partial response.
Bioniz announces positive end of Phase 2 meeting with the FDA for BNZ-1 for the treatment of refractory cutaneous T-cell lymphoma
The FDA provided positive feedback and guidance for a Phase 3 trial of BNZ-1 in rCTCL, with plans to start enrollment in the second half of 2021.
Bioniz Therapeutics reports top-line Phase 1 clinical study results for BNZ-1, a novel multi-cytokine inhibitor
Favorable safety, pharmacokinetics, and pharmacodynamic activity demonstrated in healthy volunteers, supporting further clinical development.
Bioniz Therapeutics initiates Phase 1/2 clinical study of BNZ-1 in T-cell leukemia and lymphoma
A multi-center, open-label, dose-escalation study to assess safety and activity of BNZ-1 in patients with T-cell malignancies.
Bioniz Therapeutics announces positive clinical data of BNZ-1 in refractory CTCL
BNZ-1 showed an overall response rate of 63.2%, with a complete response in one patient and partial responses in eleven, demonstrating efficacy in heavily pretreated patients.